ArticleBMC medical genomics2025
Serum miR-141-3p serves as a biomarker for early-stage diagnosis of endometriosis.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Value of Circulating Endometrial Cells in the Diagnosis and Stratified Diagnosis of Endometriosis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study is conducted to investigate whether serum microRNA (miR)-141-3p can serve as a biomarker for early-stage diagnosis of endometriosis.
methodsA total of 246 patients who underwent laparoscopic examination and were diagnosed with endometriosis at our hospital between October 2020 and October 2022 were retrospectively enrolled as the Endometriosis group. This group was further allocated into Early-Endometriosis (Stage I-II) and Severe-Endometriosis (Stage III-IV) groups. Additionally, 87 healthy women with normal clinical parameters during the same period were selected as the control group. miR-141-3p expression in the serum of endometriosis patients were detected using RT-qPCR. The relationship of serum miR-141-3p expression with EHP-30 score in endometriosis patients was examined using Spearman. The diagnostic value of serum miR-141-3p for endometriosis was assessed by ROC analysis. Further ROC analysis was conducted to evaluate the diagnostic value of combined serum miR-141-3p and CA125 levels for early-stage endometriosis.
resultsSerum miR-141-3p expression was significantly lower in endometriosis patients and was negatively correlated with clinical staging. Serum miR-141-3p demonstrated excellent diagnostic performance for endometriosis (AUC = 0.916) and retained a high diagnostic value for early-stage endometriosis (AUC = 0.858). The diagnostic efficacy was further improved when combined with CA125 (AUC = 0.985).
conclusionSerum miR-141-3p expression decreases with disease progression in endometriosis patients and shows high clinical utility for the early-stage diagnosis of endometriosis. miR-141-3p expression may serve as a potential marker for diagnosis of endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.